ArriVent BioPharma (NASDAQ:AVBP) Sees Strong Trading Volume – What’s Next?

Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) saw unusually-high trading volume on Wednesday. Approximately 685,107 shares traded hands during mid-day trading, an increase of 9% from the previous session’s volume of 625,904 shares. The stock last traded at $16.0720 and had previously closed at $15.09.

Trending Headlines about ArriVent BioPharma

Here are the key news stories impacting ArriVent BioPharma this week:

• Negative Sentiment: ArriVent announced that the Phase 3 FURVENT trial of firmonertinib in previously untreated patients with EGFR exon 20 insertion-mutated non-small cell lung cancer failed to meet its primary endpoint of progression-free survival, as assessed by blinded independent central review. The result raises substantial doubts about the drug’s approval prospects in this indication. ArriVent FURVENT trial update
• Negative Sentiment: The failed trial involves ArriVent’s lead clinical asset, prompting reports that the company is reassessing its plans for firmonertinib and resetting its investment case. The setback could lead to delays, additional development costs, or reduced investment in the program. ArriVent reviews firmonertinib plans
• Negative Sentiment: The announcement triggered a temporary trading halt and a sharp selloff, with AVBP reaching a new one-year low. The reaction reflects investors’ concerns over the company’s reduced pipeline value and uncertain path forward. ArriVent shares decline after FURVENT failure
• Negative Sentiment: Levi & Korsinsky announced a pending investigation into ArriVent following the stock decline. The notice highlights that shareholders were holding the stock near a 52-week low after the failed trial and notes the company had launched a $250 million at-the-market offering roughly five months earlier, adding potential legal and financing overhang. ArriVent investigation notice

Wall Street Analyst Weigh In

A number of brokerages have weighed in on AVBP. BTIG Research cut their target price on shares of ArriVent BioPharma from $42.00 to $29.00 and set a “buy” rating on the stock in a research report on Wednesday. Truist Financial lowered their price target on shares of ArriVent BioPharma from $45.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday. Jefferies Financial Group set a $18.00 price objective on ArriVent BioPharma in a research note on Tuesday. Guggenheim reduced their price target on shares of ArriVent BioPharma from $45.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of ArriVent BioPharma in a report on Friday, July 17th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $33.12.

ArriVent BioPharma Stock Performance

The firm has a 50 day simple moving average of $29.57 and a 200 day simple moving average of $29.43. The firm has a market cap of $795.44 million, a P/E ratio of -4.46 and a beta of 1.34.

ArriVent BioPharma (NASDAQ:AVBP) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.06). Sell-side analysts predict that ArriVent BioPharma, Inc. will post -4.11 EPS for the current fiscal year.

Institutional Investors Weigh In On ArriVent BioPharma

Large investors have recently made changes to their positions in the business. Quantbot Technologies LP purchased a new position in ArriVent BioPharma during the second quarter valued at approximately $59,000. Bank of New York Mellon Corp increased its holdings in shares of ArriVent BioPharma by 3.2% during the first quarter. Bank of New York Mellon Corp now owns 75,448 shares of the company’s stock valued at $1,741,000 after acquiring an additional 2,337 shares in the last quarter. Jupiter Topco LLC acquired a new stake in shares of ArriVent BioPharma during the second quarter worth $226,000. Arizona State Retirement System acquired a new stake in ArriVent BioPharma during the 2nd quarter worth about $233,000. Finally, Glenmede Trust Co. NA purchased a new stake in ArriVent BioPharma in the first quarter valued at approximately $209,000. 9.48% of the stock is currently owned by institutional investors.

About ArriVent BioPharma

ArriVent BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with genetically defined cancers. The company seeks to identify promising therapies developed in other regions and advance them through clinical development and regulatory approval in the United States and other markets.

ArriVent’s lead product candidate is furmonertinib, an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to target specific EGFR mutations in non-small cell lung cancer, including EGFR exon 20 insertion mutations.